0000000000193907

AUTHOR

Ana Blasco

showing 39 related works from this author

Impact of burn-out syndrome in oncology personnel and its improvement through specific interventions

2019

Abstract Background Burn-Out Syndrome (BOS) in oncology nurses, has few experiences reported about its incidence and impact in its three different areas: emotional and physical exhaustion, cynism and despersonalization and no personal nor profesional fulfillment. There is a lack of resources for its diagnosis and management, although it impacts negatively in the patient attention/ care quality and the quality of institutional processes, added the personal impact in personal workers lives. Our objective was to determine the incidence of the BOS in our workers, analyze its causes and reduce in 20% the percentage of workers suffering or at risk of suffering BOS. Methods 23 nurses / nurse assis…

Oncologymedicine.medical_specialtybusiness.industryIncidence (epidemiology)Burn outConflict of interestPsychological interventionHematologyBurnouthumanitiesOncologyIntervention (counseling)Internal medicineMedicineGeneral Health QuestionnairebusinessPersonal detailsAnnals of Oncology
researchProduct

Prognostic value of CTCs in advanced NSCLC patients treated with platinum-based chemotherapy

2019

Abstract Background Lung cancer is the leading cause of cancer-related mortality worldwide. At diagnosis, 70% of patients present advanced disease being chemotherapy the standard of care. Although, specific tumour biomarkers that allow a better treatment selection and monitoring is absent at the moment. Enumeration and characterization of circulating tumor cells (CTCs) have the potential to perform as a prognostic biomarker for a precision medicine approach to lung cancer care. The present study was conducted to validate the characterization CTCs from patients with advanced Non-small cell lung cancer (NSCLC) as a valuable tool for anticipating the disease evolution and the therapy response.…

Oncologymedicine.medical_specialtyChemotherapybusiness.industrymedicine.medical_treatmentHematologyPrecision medicinemedicine.diseaseCirculating tumor cellOncologyInternal medicinemedicineAdvanced diseasePrognostic biomarkerChristian ministryNon small cellLung cancerbusinessAnnals of Oncology
researchProduct

Abstract 4010: Prognostic role of miRNAs in resectable non-small cell lung cancer

2015

Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA BACKGROUND MicroRNAs (miRNA) are a class of small RNAs that regulate gene expression, and are implicated in several diseases including cancer. The aim of this study was to analyze the prognostic implications of deregulated miRNAs identified by NGS in a previous study performed on resectable-NSCLC tumor samples. MATERIAL AND METHODS Fresh-frozen tumor and normal adjacent lung tissue samples (N = 195) were obtained by surgical resection from NSCLC patients and storage in RNAlater® at -80°C until analysis. RNA was isolated biological specimens by Trizol based-methods. 22 deregulated miRNA were analyzed in paired t…

OncologyCancer Researchmedicine.medical_specialtyUnivariate analysisPathologyPerformance statusbusiness.industryCancermedicine.diseaseContinuous variableOncologyInternal medicinemicroRNAmedicineNon small cellbusinessLung cancerSurvival analysisCancer Research
researchProduct

Tumor expression levels of CSC markers in resectable non-small cell lung cancer.

2014

7562 Background: Cancer stem cells (CSCs) have been proposed as the driving force of tumorigenesis and the seeds of metastases. However, their existence and role remain a topic of intense debate. T...

Cancer ResearchOncologybusiness.industryCancer stem cellCancer researchmedicineNon small cellLung cancermedicine.diseasebusinessCarcinogenesismedicine.disease_cause
researchProduct

Lung tumorspheres reveal cancer stem cell-like properties and a score with prognostic impact in resected non-small-cell lung cancer

2019

AbstractThe high resistance against current therapies found in non-small-cell lung cancer (NSCLC) has been associated to cancer stem-like cells (CSCs), a population for which the identification of targets and biomarkers is still under development. In this study, primary cultures from early-stage NSCLC patients were established, using sphere-forming assays for CSC enrichment and adherent conditions for the control counterparts. Patient-derived tumorspheres showed self-renewal and unlimited exponential growth potentials, resistance against chemotherapeutic agents, invasion and differentiation capacities in vitro, and superior tumorigenic potential in vivo. Using quantitative PCR, gene express…

0301 basic medicineOncologyMaleCancer ResearchCellular pathologyLung NeoplasmsTumour biomarkersMice0302 clinical medicineMice Inbred NODCarcinoma Non-Small-Cell LungAged 80 and overeducation.field_of_studybiologylcsh:CytologyCancer stem cellsMiddle AgedStem-cell researchNeoplasm ProteinsGene Expression Regulation Neoplastic030220 oncology & carcinogenesisCarcinoma Squamous CellNeoplastic Stem CellsAdenocarcinomaFemaleAdultmedicine.medical_specialtyImmunologyPopulationAdenocarcinoma of LungArticle03 medical and health sciencesCellular and Molecular NeuroscienceCancer stem cellInternal medicineSpheroids CellularmedicineCarcinomaAnimalsHumanslcsh:QH573-671educationLung cancerSurvival analysisAgedbusiness.industryCD44Cell Biologymedicine.disease030104 developmental biologyA549 Cellsbiology.proteinbusinessNon-small-cell lung cancer
researchProduct

MicroRNA profiling associated with non-small cell lung cancer: next generation sequencing detection, experimental validation, and prognostic value

2017

[EN] Background: The average five-year survival for non-small cell lung cancer (NSCLC) patients is approximately 15%. Emerging evidence indicates that microRNAs (miRNAs) constitute a new class of gene regulators in humans that may play an important role in tumorigenesis. Hence, there is growing interest in studying their role as possible new biomarkers whose expression is aberrant in cancer. Therefore, in this study we identified dysregulated miRNAs by next generation sequencing (NGS) and analyzed their prognostic value. Methods: Sequencing by oligo ligation detection technology was used to identify dysregulated miRNAs in a training cohort comprising paired tumor/normal tissue samples (N = …

0301 basic medicineOncologymedicine.medical_specialtyPathologyBIOLOGIA CELULARNSCLCDNA sequencing03 medical and health sciences0302 clinical medicineInternal medicineMedicineLung cancerValenciaSurvival analysisbiologybusiness.industryProportional hazards modelProfilingExperimental validationbiology.organism_classificationmedicine.diseasePrognosismicroRNAsMicroRNAs030104 developmental biologyOncology030220 oncology & carcinogenesisNGSNon small cellPersonalized medicineprognosisprofilingbusinessResearch Paper
researchProduct

Immune Checkpoints Score and CD8+ T Cells Infiltration Are Independent Prognostic Biomarkers in Resected Nsclc

2015

Pathologymedicine.medical_specialtyOncologybusiness.industryMedicineCytotoxic T cellHematologyT lymphocytebusinessmedicine.diseaseInfiltration (medical)Annals of Oncology
researchProduct

Oncology beyond the hospital: 7 years taking care of cancer patients from the very begining until the last consequences.

2017

75 Background: Comprehensive and continuous care is esential for the correct management of cancer patients. To achieve this, specific programs for early diagnosis and long survivor care are needed. Since 2007, within the project “Oncology beyond the Hospital: Oncologic assistance at the Universitary General Hospital of Valencia”, the Oncologist Liaison was created. Methods: Two tracks were designed: High-resolution track for patients with suspicion of non-diagnosed cáncer; and Oncologist Liaison track, to organize the follow-up of cáncer long survivors. We present a descriptive and retrospective study by reviewing medical records of patients referred to the high-resolution diagnostic consu…

OncologyCancer Researchmedicine.medical_specialtybusiness.industryMedical recordPrimary care physicianCancerRetrospective cohort studymedicine.diseaseOncologyInternal medicinemedicineGeneral hospitalbusinessJournal of Clinical Oncology
researchProduct

Differential expression of tumorspheres in CSC-markers and signaling pathways from non-small cell lung cancer.

2016

e23276Background: Chemoresistance, tumor progression and metastasis have made of lung cancer the first cause of death cancer-related worldwide. Cancer stem cells (CSCs) are small subpopulations of ...

Cancer Researchbusiness.industrymedicine.diseaseMetastasisOncologyTumor progressionCancer stem cellCancer researchMedicineNon small cellSignal transductionDifferential expressionbusinessLung cancerCause of deathJournal of Clinical Oncology
researchProduct

MiRNA profiling by NGS in resectable non-small cell lung cancer: Prognostic implications.

2014

7559 Background: MicroRNAs (miRNA) regulate gene expression, and are implicated in several processes like tumorogenesis. Here, we applied a multiplexed NGS approach to study differentially expressed miRNAs (tumor/ normal) in a cohort of resectable NSCLC patients and its correlation with clinical outcome. Methods: RNA was isolated from frozen lung specimens (tumor/ normal) from 33 patients. High-quality samples were analyzed and enriched in the miRNA fraction. Libraries were prepared according to manufactured instruction (SOLID), and miRNAs were sequenced. Data analysis was carried out using CLCbio software. First, raw data were annotated using miRBase and normalized by total reads followed …

Cancer ResearchIn silicoRNAComputational biologyBiologyBioinformaticsmedicine.diseaseMiRBaseOncologymicroRNAGene expressionmedicineMirna profilingNon small cellLung cancer
researchProduct

Upregulated Mirna 21 in Kras Mutated Patients is Related to Prognosis in Resectable Non-Small Cell Lung Cancer

2015

Oncologymedicine.medical_specialtybusiness.industryHematologymedicine.diseasemedicine.disease_causeOncologyInternal medicineMutation (genetic algorithm)microRNAmedicineNon small cellKRASbusinessLung cancerAnnals of Oncology
researchProduct

P1.05-013 Lung Tumorspheres as a Platform for Testing New Therapeutic Strategies in Non-Small Cell Lung Cancer

2017

Pulmonary and Respiratory MedicineOncologymedicine.medical_specialtyLungbusiness.industryTranslational researchmedicine.diseasemedicine.anatomical_structureOncologyInternal medicineMedicineNon small cellbusinessLung cancerJournal of Thoracic Oncology
researchProduct

Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer

2017

Abstract: Introduction: The discovery of driver mutations in non-small cell lung cancer (NSCLC) has led to the development of genome-based personalized medicine. Fifteen to 20% of adenocarcinomas harbor an epidermal growth factor receptor (EGFR) activating mutation associated with responses to EGFR tyrosine kinase inhibitors (TKIs). Individual laboratories' expertise and the availability of appropriate equipment are valuable assets in predictive molecular pathology, although the choice of methods should be determined by the nature of the samples to be tested and whether the detection of only well-characterized EGFR mutations or rather, of all detectable mutations, is required.Areas covered:…

0301 basic medicineLung NeoplasmsEGFRDNA Mutational Analysis2734Real-Time Polymerase Chain Reactionmedicine.disease_causeBioinformaticsGenomePathology and Forensic Medicineresistance03 medical and health sciences0302 clinical medicineCarcinoma Non-Small-Cell LungGeneticsHumansMedicineEpidermal growth factor receptorLiquid biopsyLung cancerMolecular Biologycobas®Mutationliquid biopsybiologyReverse Transcriptase Polymerase Chain Reactionbusiness.industryMolecular pathologymedicine.diseaseTKIErbB Receptors030104 developmental biology030220 oncology & carcinogenesisCancer researchbiology.proteinMolecular Medicinecompanion diagnosticHuman medicineReagent Kits DiagnosticPersonalized medicinemutationbusinessCompanion diagnosticExpert Review of Molecular Diagnostics
researchProduct

Analysis of immunoregulatory biomarkers in early stages of non-small cell lung cancer

2017

Oncologybusiness.industrymedicineCancer researchHematologyNon small cellLung cancermedicine.diseasebusinessAnnals of Oncology
researchProduct

EGFR mutant cfDNA and CTC detection as biomarkers in patients diagnosed with advanced non-small cell lung cancer.

2016

e23039Background: One of the most promising developments in translational cancer has been the emergence of liquid biopsy as a non-invasive biomarker. CTCs and cfDNA offer valuable prognostic and pr...

Cancer Researchbusiness.industryMutantCancermedicine.diseaseOncologyCancer researchMedicineBiomarker (medicine)In patientNon small cellLiquid biopsybusinessLung cancerJournal of Clinical Oncology
researchProduct

Applicability of ctDNA at diagnosis and during the monitoring of EGFR-mutated patients

2019

Oncologybusiness.industryCirculating tumor DNAMutation (genetic algorithm)Cancer researchMedicineHematologybusinessAnnals of Oncology
researchProduct

Analysis of the immune microenvironment in resected non-small cell lung cancer: the prognostic value of different T lymphocyte markers

2016

[EN] The prognosis of non-small cell lung cancer (NSCLC) remains poor and heterogeneous and new biomarkers are needed. As the immune system plays a pivotal role in cancer, the study of immune-related markers may provide valuable prognostic information of NSCLC. In 122 formalin-fixed, paraffin-embedded tumor tissue samples from early-stage NSCLC, tumor and tumor-near stromal areas were microdissected and gene expression levels of conventional and regulatory T cell markers were assessed by quantitative polymerase chain reaction. Also, the presence of infiltrating CD4+, CD8+, and FOXP3+ cells in tumor samples was assessed by immunohistochemistry. The relative proportion of conventional and reg…

0301 basic medicineMalePathologyLung NeoplasmsT-LymphocytesBIOLOGIA CELULARKaplan-Meier EstimateNSCLC0302 clinical medicineT-Lymphocyte SubsetsCarcinoma Non-Small-Cell LungTumor MicroenvironmentCytotoxic T cellAged 80 and overFOXP3Forkhead Transcription FactorsMiddle AgedPrognosismedicine.anatomical_structureOncology030220 oncology & carcinogenesisCD4 AntigensFemaleAdultmedicine.medical_specialtyStromal cellRegulatory T cellCD8 Antigensimmune-biomarkerPrognostic03 medical and health sciencesImmune systemmedicineBiomarkers TumorResearch Paper: Autophagy and Cell DeathHumansImmune biomarkerTumor stromaTumor compartmentAgedTumor microenvironmentbusiness.industryVDP::Medical disciplines: 700::Clinical medical disciplines: 750::Oncology: 762tumor stromaCancermedicine.disease030104 developmental biologyImmune-biomarkerCancer researchimmunebusinessprognosticCD8
researchProduct

Lung tumorspheres as a drug screening platform against cancer stem cells.

2019

Treatment resistance and metastasis are linked to cancer stem cells (CSCs). This population represents a promising target, but remains unexplored in lung cancer. The main objective of this study was to characterize lung CSCs and discover new therapeutic strategies.

Drugcancer stem cellsLungbusiness.industrymedia_common.quotation_subjectHematologyrespiratory systemrespiratory tract diseasesmedicine.anatomical_structureOncologyCancer stem celllung tumorspheresCancer researchmedicinebusinessdrug screening platformmedia_common
researchProduct

Prognostic role of immune checkpoint-related genes in resectable lung adenocarcinomas.

2014

11085 Background: Immune checkpoints blockade has demonstrated promising clinical results in NSCLC patients. In this study we have investigated the prognostic role of immune checkpoint markers (CTLA4, PD1 and PDL1) in resectable lung adenocarcinoma (ADC). Methods: RNA was isolated from fresh-frozen lung specimens (tumor and normal lung) from resectable ADC patients (n=92). RT-PCR was performed to analyze the expression of CTLA4, PD1 and PDL1 by the use of hydrolysis probes. Relative gene expression was assessed by Pfaffl formula and normalized by CDKN1B and ACTB as endogenous genes (selected by geNorm algorithm). Statistical analyses were considered significant at p<0.05. Results: Patient’s…

OncologyCancer Researchmedicine.medical_specialtyPathologyLungPerformance statusbusiness.industrymedicine.diseaseImmune checkpointBlockademedicine.anatomical_structureImmune systemOncologyInternal medicineGene expressionmedicineAdenocarcinomaCDKN1BbusinessJournal of Clinical Oncology
researchProduct

Soluble biomarker signature to predict outcome of patients with non-small-cell lung cancer (NSCLC) treated with anti-PD1/PDL1 monoclonal antibodies.

2019

e20685 Background: Immunotherapy with anti-PD1/PDL1 monoclonal antibodies has become the second line standard treatment for most patients diagnosed of advanced Non-Small-Cell lung cancer (NSCLC). The aim of this study is to assess the utility of circulating biomarkers such as sPDL1, sPDL2, sCD137, sIDO, sTIM3, sCD28, sCD27, sCTLA4, sHVEM, sLAG3, sCD80 and sGITR for predicting efficacy of immunotherapy with anti-PD1/PDL1 therapies. Methods: Blood samples were collected before treatment from 50 NSCLC patients who received anti PD1/PDL1 therapies (second line). Plasma biomarkers´ levels were measured by Multiplex bead-based assays. Continuous variables were categorized using the median as a c…

Cancer Researchmedicine.drug_classbusiness.industrymedicine.medical_treatmentStandard treatmentnon-small cell lung cancer (NSCLC)Immunotherapymedicine.diseaseMonoclonal antibodySecond lineOncologymedicineCancer researchBiomarker (medicine)Lung cancerAnti pd1businessJournal of Clinical Oncology
researchProduct

Analysis of gut microbiota in advanced non-small cell lung cancer (NSCLC) patients treated with immune-checkpoints blockers

2019

Abstract Background The microbiota community is considered as an organ of the human body. Recent studies have found that dysbiosis may have an impact on the interaction between immune regulation and tumor treatment. The main objective of this study is to characterize the gut microbiota in patients with non-small cell lung cancer (NSCLC) in advanced stages, and its relationship with obesity, smoking habits, clinical pathological features and response to treatment with immune-checkpoints blockers (ICB). Methods 16S rRNA gene sequencing was performed on 48 stool samples from advanced NSCLC patients prior to treatment with ICB (PD-1 inhibitor and PD-L1 inhibitor). The database used for the taxo…

medicine.medical_specialtybiologybusiness.industrynon-small cell lung cancer (NSCLC)HematologyDiseaseGut floramedicine.diseasebiology.organism_classificationGastroenterologyOncologyInternal medicinemedicinePrevotellaAdenocarcinomaMicrobiomebusinessAlistipesDysbiosisAnnals of Oncology
researchProduct

Prognostic Impact of Vegfa in Resectable Non-Small-Cell Lung Cancer

2014

ABSTRACT Aim: Angiogenesis is a main process which happens in tumors and that promotes its growth, invasive capacity and metastasis. Host genetic variability within VEGF pathway may affect angiogenic signaling and alter patient's sensitivity to anti-angiogenic therapies and therefore the prognostic. The goal in the present study is to analyze the prognostic value of several SNPs in angiogenic genes and the relative expression of those genes, using a cohort of patients diagnosed with resectable non-small cell lung cancer. Methods: This study included 127 resectable (I-IIIA) NSCLC patients. RNA and DNA extractions from tissues were performed using Trizol®. 20 ng of DNA were used for studies o…

Oncologymedicine.medical_specialtyPathologybusiness.industrySingle-nucleotide polymorphismHematologymedicine.diseaseMetastasisVascular endothelial growth factor AOncologyInternal medicineGenotypemedicineTaqManAdenocarcinomabusinessLung cancerSurvival analysisAnnals of Oncology
researchProduct

Lung tumorspheres as a platform for testing new therapeutic strategies in lung cancer.

2016

e23177Background: Resistance to treatment is one of the causes influencing the high mortality of lung cancer. This feature seems to be dependent of a small subset of special characteristics of self...

OncologyCancer Researchmedicine.medical_specialtyLungbusiness.industryHigh mortalitymedicine.diseasemedicine.anatomical_structureOncologyFeature (computer vision)Internal medicinemedicineTreatment resistancebusinessLung cancer
researchProduct

Analysis of Exosomal Cargo Provides Accurate Clinical, Histologic and Mutational Information in Non-Small Cell Lung Cancer

2022

Simple Summary Non-small cell lung cancer (NSCLC) is the second most commonly diagnosed cancer and the leading cause of cancer-related death worldwide. Clinical decision-making depends on the histological classification; however, tissue biopsy is frequently not technically feasible due to tumor location or limited tissue samples. Therefore, we propose to find clinical, molecular and histological biomarkers using a minimally invasive approach based on the analysis of the cargo of the blood extracellular vesicles. Exosomes are membranous vesicles present in several biological fluids, which carry biological information to distant tissues, regulating several tumor processes. This study aims to …

squamous cell carcinomaCancer ResearchtumorspheresMICRORNASBIOMARKERSCANCER/TESTIS ANTIGENexosomesNSCLCnon-small cell lung cancer; liquid biopsy; exosomes; extracellular vesicles; cell cultures; adenocarcinoma; squamous cell carcinoma; biomarker; tumorspheresMECHANISMSRNASMICROARRAYIMMUNOTHERAPYCàncernon-small cell lung cancerScience & Technologyadenocarcinomaliquid biopsycell culturesSTATISTICSOncologyPulmonsbiomarkerextracellular vesiclesLife Sciences & Biomedicine
researchProduct

Abstract 1918: Gene characterization of lung-tumorspheres for their usage as an in vitro screening platform for testing new therapeutic strategies

2017

Abstract Background: Lung cancer features like treatment resistance or tumor relapse have been linked to cancer stem cells (CSCs), a population of cells with self-renewal properties, and the ability to grow forming tumorspheres in non-adherent conditions. The aim of this study was to isolate and characterize tumorspheres from lung cancer cell lines and tumor tissue from resectable non-small cell lung cancer (NSCLC) patients and to use them as an in vitro platform for drug screening. Methods: This study was performed on cells from seven NSCLC tumor samples and five cell lines (H1650, H1993, H1395, A549 and PC9) grown in monolayer and as spheroids. The expression of 60 genes, including CSC-ma…

Cancer ResearchbiologyCD44Notch signaling pathwayWnt signaling pathwayCancerVismodegibmedicine.diseaseVinorelbineBioinformaticsOncologyCancer stem cellmedicinebiology.proteinCancer researchLung cancermedicine.drugCancer Research
researchProduct

Analysis of the Gut Microbiota: An Emerging Source of Biomarkers for Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer

2021

Simple Summary The immune checkpoint blockade (ICB), and concretely the blockade of the PD1/PDL1 axis, has opened up a new standard of treatment for non-small cell lung cancer (NSCLC). However, despite substantial advances in clinical care, many patients still remain refractory to these therapies. Biomarkers such as PD-L1 expression and tumor mutational burden have been associated with ICB efficacy, but the mechanisms underlying variable responses are not yet fully understood. Recently, the differential composition of the gut microbiota was studied as one of the variables accounting for interpatient heterogeneity in ICB responses. To better understand the potential role of the gut microbiot…

0301 basic medicineCancer Researchmedicine.drug_classmedicine.medical_treatmentAntibioticsGut floradigestive systemArticle03 medical and health sciences0302 clinical medicinemedicineLung cancerRC254-282non-small cell lung cancerbiologygut microbiotabusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensImmunotherapyimmune checkpoint blockademedicine.diseasebiology.organism_classificationImmune checkpointBlockade030104 developmental biologyOncology030220 oncology & carcinogenesisImmunologyBiomarker (medicine)biomarkernext-generation sequencingimmunotherapybusinessProgressive disease
researchProduct

New insights in non-small-cell lung cancer: circulating tumor cells and cell-free DNA

2017

Lung cancer is the second most frequent tumor and the leading cause of death by cancer in both men and women. Increasing knowledge about the cancer genome and tumor environment has led to a new setting in which morphological and molecular characterization is needed to treat patients in the most personalized way in order to achieve better outcomes. Since tumor products can be detected in body fluids, the liquid biopsy, particularly, peripheral blood, has emerged as a new source for lung cancer biomarker's analysis. A variety of tumor components can be used for this purpose. Among them, circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) should be especially considered. Different…

0301 basic medicinePulmonary and Respiratory MedicineOncologymedicine.medical_specialtybiologybusiness.industrynon-small cell lung cancer (NSCLC)CancerReview Articlemedicine.disease03 medical and health sciences030104 developmental biology0302 clinical medicineCirculating tumor cellCell-free fetal DNA030220 oncology & carcinogenesisInternal medicineImmunologymedicinebiology.proteinBiomarker (medicine)Epidermal growth factor receptorLiquid biopsyLung cancerbusiness
researchProduct

MA04.03 Lung Tumorspheres Characterization Reveals Cancer Stem-Like Cells Potential Targets and Prognostic Markers in Non-Small Cell Lung Cancer

2019

Pulmonary and Respiratory MedicineLungmedicine.anatomical_structureOncologybusiness.industryCancer researchMedicineCancerNon small cellbusinessmedicine.diseaseLung cancerJournal of Thoracic Oncology
researchProduct

Impact of burn-out syndrome in oncology staff and its improvement through specific interventions.

2019

249 Background: Burn-Out Syndrome (BOS) is defined by: emotional and physical exhaustion; cynicism and depersonalization; and no personal nor professional fulfillment. With increasing incidence, it impacts negatively in the patient attention quality and the quality of institutional processes. Few experiences reported about its incidence and impact in Medical Oncology. Lack of resources for its diagnosis and management. Our objective was to determine the incidence of the BOS in our workers, analyze its causes and try to reduce in 20% the percentage of workers suffering or at risk of suffering BOS. Developed as a Quality Training Program (ASCO - ECO Foundation) project. Methods: 23 nurses/nu…

Cancer Researchmedicine.medical_specialtybusiness.industryIncidence (epidemiology)Burn outPsychological interventionhumanities03 medical and health sciences0302 clinical medicineCynicismOncology030220 oncology & carcinogenesisDepersonalizationmedicinePhysical exhaustionmedicine.symptomPsychiatrybusiness030215 immunologyJournal of Clinical Oncology
researchProduct

Comprehensive cross-platform comparison of methods for non-invasive EGFR mutation testing : results of the RING observational trial

2020

Plasma samples from 72 EGFR‐mutant advanced NSCLC patients, collected upon progression to first‐line TKI, were analyzed by seven methodologies (two NGS‐based methods, three high‐sensitivity PCR‐based platforms, and two FDA‐approved methods). Our study demonstrates a good to excellent agreement between methodologies and supports the use of liquid biopsies for therapy decision‐making.

0301 basic medicineOncologyMaleCancer Researchcell lung cancerIntraclass correlationBiopsyDNA Mutational Analysisnon-small cell lung cancer (NSCLC)Tyrosine kinase inhibitorTyrosine-kinase inhibitorCohort Studies*circulating free DNAT790M0302 clinical medicinetyrosine kinase inhibitorGene FrequencyOsimertinibProspective cohort studyCàncernon‐small‐cell lung cancerCirculating free DNARC254-282Research ArticlesSequence DeletionAged 80 and overNeoplasms. Tumors. Oncology. Including cancer and carcinogensHigh-Throughput Nucleotide Sequencingnon&#8208General MedicineDNA NeoplasmExonsMiddle AgedErbB ReceptorsEpidermal growth factor receptor (EGFR) NGS Non-small cell lung cancer (NSCLC) PCR Tyrosine Kinase Inhibitor (TKI) circulating free DNA (cfDNA) osimertinibOncology030220 oncology & carcinogenesisosimertinibNGSMolecular Medicinesmall&#8208FemaleResearch Article*NGSAdultmedicine.medical_specialtymedicine.drug_classSensitivity and Specificity03 medical and health sciencesPredictive Value of TestsInternal medicineGeneticsmedicineHumansAged*non-small-cell lung cancerbusiness.industryEpidermal growth factor receptorNon invasive*epidermal growth factor receptormedicine.disease*tyrosine kinase inhibitorrespiratory tract diseases030104 developmental biologyEgfr mutationPulmonsMutationcirculating free DNAbusinessepidermal growth factor receptorNon-small-cell lung cancer*osimertinibOsimertinib
researchProduct

Serum metabolomic profiling facilitates the non-invasive identification of metabolic biomarkers associated with the onset and progression of non-smal…

2016

Lung cancer (LC) is responsible for most cancer deaths. One of the main factors contributing to the lethality of this disease is the fact that a large proportion of patients are diagnosed at advanced stages when a clinical intervention is unlikely to succeed. In this study, we evaluated the potential of metabolomics by H-1-NMR to facilitate the identification of accurate and reliable biomarkers to support the early diagnosis and prognosis of non-small cell lung cancer (NSCLC). We found that the metabolic profile of NSCLC patients, compared with healthy individuals, is characterized by statistically significant changes in the concentration of 18 metabolites representing different amino acids…

0301 basic medicineGerontologyOncologyAdultMalemedicine.medical_specialtyLung NeoplasmsProton Magnetic Resonance SpectroscopyDiseaseNSCLC03 medical and health sciences0302 clinical medicineMetabolomicsInternal medicineCarcinoma Non-Small-Cell LungmedicineBiomarkers TumorHumansLung cancerAgedbusiness.industryNon invasivebiomarkersLipid metabolismMiddle Agedmedicine.diseasemetabolomicsPathophysiology030104 developmental biologyMetabolomic profilingOncology030220 oncology & carcinogenesisDisease ProgressionFemaleNon small cellprognosisbusinessResearch Paperearly diagnosis
researchProduct

Characterization of lung tumourspheres reveals cancer stem-like cells potential targets and prognostic markers in non-small cell lung cancer

2019

Abstract Background Non-small cell lung cancer (NSCLC) is the first cause of death cancer-related worldwide mainly due to high therapeutic resistance. This resistance is related to cancer stem-like cells (CSCs), for which the identification of targets and markers is still ongoing. Methods Primary cultures from 8 NSCLC patients were established as tumorspheres and as monolayers. CSCs properties were tested for both conditions in vitro and in vivo. The expression of 50 CSCs-related genes was assessed by RTqPCR and proteins of significantly overexpressed genes were examined by immunoblot and immunofluorescence. The prognostic role of these genes was analyzed in a cohort of 661 NSCLC patients f…

OncologyHomeobox protein NANOGmedicine.medical_specialtybiologybusiness.industryCD44CancerHematologymedicine.diseaseOncologyInternal medicineCohortbiology.proteinmedicineAdenocarcinomaBiomarker (medicine)businessLung cancerITGA6Annals of Oncology
researchProduct

Analysis of the prognostic impact of Treg-related genes in tumor and stroma in resectable NSCLC

2013

11073 Background: Immunosuppressive regulatory T lymphocytes (Tregs) have been proved to play a critical role in immune tolerance to tumor. In this study we have analyzed the expression of 11 genes related to Tregs in both tumor and stroma samples of resectable NSCLC patients. Methods: Primary tumor tissues of FFPE samples from 125 early-stage NSCLC patients were used in this retrospective study. The most representative areas of tumor cells and tumor stroma of each sample were carefully micro-dissected. RTqPCR using hydrolysis probes (TaqMan, Applied Biosystems) was performed to assess the expression of Treg markers such as: CD127, CD25, FOXP3, CTLA-4, IL-10, TGFB-1, LAG-3, GITR and TNF-a …

Cancer ResearchPathologymedicine.medical_specialtybusiness.industryFOXP3hemic and immune systemschemical and pharmacologic phenomenamedicine.diseasePrimary tumorImmune toleranceOncologyStromaCancer researchTaqManMedicineIL-2 receptorbusinessInterleukin-7 receptorCD8
researchProduct

Analysis of the prognostic role of an immune checkpoint score in resected non-small cell lung cancer patients

2016

[EN] Tumors develop mechanisms to recruit tolerogenic immune cells and to induce the expression of molecules that act as immune checkpoints. This regulation of the immune microenvironment favors immune tolerance to the neoplastic cells. In this study, we have investigated the prognostic role of immune-checkpoint expression markers in a cohort of resectable non-small cell lung cancer (NSCLC) patients. RNA was isolated from fresh-frozen lung specimens (tumor and normal lung) (n = 178). RTqPCR was performed to analyze the relative expression of 20 immune-related genes that were normalized by the use of endogenous genes selected by GeNorm algorithm. Patients with higher expression levels of IL2…

0301 basic medicineImmunologyBIOLOGIA CELULARchemical and pharmacologic phenomenaEndogenyBiologyNSCLCPrognosticImmune tolerance03 medical and health sciences0302 clinical medicineImmune systemmedicineImmunology and AllergyLung cancerGeneOriginal ResearchCheckpoint scoreLungBiomarkermedicine.diseaseImmune checkpoint030104 developmental biologymedicine.anatomical_structureEditorialOncology030220 oncology & carcinogenesisImmunologyCancer researchBiomarker (medicine)
researchProduct

Abstract 3056: Lung tumor spheres as in vitro platform for testing new therapeutic strategies against cancer stem cells

2018

Abstract Background: Treatment resistance is related to cancer stem cells (CSCs), a highly tumorigenic subpopulation of cells capable of growing and forming tumor spheres under non-adherent conditions. This study aimed to isolate and characterise CSCs from resected non-small cell lung cancer (NSCLC) patients' tumor-tissue and cell lines like tumor spheres and to use them as an in vitro platform for drug screening. Methods: The study was performed on tumour cells from 8 resected NSCLC patients and 12 NSCLC cell lines grown in monolayer and as spheres. The expression of 60 genes, including CSC-markers, pluripotency inducers, cell cycle regulators and components of the Notch, Wnt and Hedgehog …

Homeobox protein NANOGCancer ResearchOncologybiologySOX2KLF4Cancer stem cellCellular differentiationCD44Cancer researchbiology.proteinCytotoxic T cellCD90Cancer Research
researchProduct

A gene expression signature to characterize human lung adenocarcinoma cancer stem cells.

2018

e20547Background: Treatment resistance is linked to cancer stem cells (CSCs), a highly tumorigenic subpopulation of cells with the ability to grow as spheres in non-adherent conditions. The aim of ...

Cancer Researchbusiness.industryExpression Signaturemedicine.diseaseHuman lungmedicine.anatomical_structureOncologyCancer stem cellmedicineCancer researchAdenocarcinomaTreatment resistancebusinessGeneJournal of Clinical Oncology
researchProduct

Isolation and characterization of lung cancer sphere-forming cells as platforms for the development of new therapeutic strategies

2015

e22190 Background: Resistance to treatment is one of major causes influencing the high mortality of lung cancer. This feature seems to be dependent of a minority of cancer cells with special charac...

Cancer ResearchOncologyIsolation (health care)business.industryCancer cellHigh mortalitymedicineCancer researchTreatment resistanceLung cancermedicine.diseasebusiness
researchProduct

Ratios between VEGF ligands and receptors in tumor and stroma have impact on the outcome in resectable NSCLC.

2013

e22147 Background: In tumor angiogenesis there is a complex interplay between endothelial, stromal and tumor cells. Some key regulators of this process are the members of the vascular endothelial growth factor (VEGF) family of ligands and receptors and the neuropilins (NRP). This study analyzes the correlations between the expression of these angiogenic factors in tumor cells and tumor stroma, and their prognostic role in tissue samples from resected non-small cell lung cancer (NSCLC) patients. Methods: Representative tumor and stroma areas from FFPE tissue samples of 125 early-stage NSCLC patients were carefully micro-dissected. RNA isolated from the samples was retrotranscripted and prea…

Tumor angiogenesisCancer ResearchStromal cellbiologybusiness.industryVEGF receptorsTumor cellsOncologyStromabiology.proteinCancer researchMedicinebusinessReceptorJournal of Clinical Oncology
researchProduct

Enfermedad de Jacob asociada con el síndrome de disfunción de la articulación temporomandibular: presentación de un caso

2005

La enfermedad de Jacob se describe como una entidad infrecuente en la cual se establece una formación articular sinovial entre una apófisis coronoide mandibular elongada y el hueso malar homolateral. El Síndrome de disfunción de la articulación temporomandibular (ATM) ha sido postulado como posible factor etiológico del alargamiento este proceso coronoideo. Presentamos el caso de una mujer de 23 años con un desplazamiento discal de ATM de larga evolución y limitación de la apertura oral, que desarrolló una asimetría malar progresiva. La paciente fue sometida a tratamiento quirúrgico mediante una coronoidectomía intraoral y una artroscopia de la ATM homolateral en el mismo acto operatorio. E…

UNESCO::CIENCIAS MÉDICASdisfunción de la articulación temporomandibularOdontologíahiperplasia apófisis coronoide:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludEnfermedad de Jacobcoronoidectomía
researchProduct